Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katherine Tillman

Registered Nurse, Administrator Fort Worth, TX Nurse Practitioner

NPI 1720648140 CMS profile 10436395

1919 8Th Ave, Fort Worth, TX 76110

Open in the dashboard

General payments

$2,808

114 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Tillman of Fort Worth, TX is reported in the CMS Open Payments database as having received $2,808 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $547 11
2024 General $695 19
2023 General $124 6
2022 General $909 41
2021 General $532 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Tillman
  • Texas median
  • Middle half of Texas
  • National median

In program year 2025, general payments to Katherine Tillman were reported at $547. Among 86,592 Texas profiles paid that year, the median was $188 and the middle half received between $55 and $669.

Show as a table
Year Katherine Tillman Texas median Middle half National median
2019 $0 $191 $56–$744 $163
2020 $0 $125 $38–$452 $114
2021 $532 $150 $43–$543 $132
2022 $909 $169 $50–$606 $149
2023 $124 $183 $53–$639 $160
2024 $695 $188 $55–$666 $164
2025 $547 $188 $55–$669 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $1,857 85 payments
  2. ViiV Healthcare Company $419 17 payments
  3. Pharming Healthcare, Inc. $172 1 payment
  4. Janssen Biotech, Inc. $136 9 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $125 1 payment
  6. Janssen Products, LP $99 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,279 112 payments
  2. Consulting Fee $430 1 payment
  3. Education $99 1 payment
Products named General payments · program years 2021–2025
  1. Biktarvy $530 2 payments
  2. DOVATO $286 10 payments
  3. Descovy $238 3 payments
  4. SYMTUZA $235 10 payments
  5. RUCONEST $172 1 payment
  6. Yeztugo $135 1 payment
  7. CUVITRU $125 1 payment
  8. APRETUDE $58 3 payments
  9. CABENUVA $51 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

38

Median for Registered Nurse: 109

Drug cost

$86,172

Median for Registered Nurse: $4,454

Branded share of claims

100%

Median for Registered Nurse: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Descovy Emtricitabine/Tenofov Alafenam Brand 38 $86,172

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Biktarvy
  • Gilead Sciences, Inc. $430
$430 — —
DOVATO
  • ViiV Healthcare Company $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Administrator in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record